In the ARAMIS study, darolutamide was demonstrated to be effective and well tolerated in patients with nmCRPC. We present efficacy and safety outcomes of 52 Black/African-American patients who took part in the ARAMIS study.
Subscribe: [ Ссылка ]
Visit The Video Journal of Biomedicine: [ Ссылка ]
Follow us on Twitter: [ Ссылка ]
LinkedIn: [ Ссылка ]
Facebook: [ Ссылка ]
#Darolutamide #ProstateCancer #nmCRPC #Black #African-American
